2921 results about "Side effect" patented technology

The invention discloses a xanthine oxidase inhibitory peptide with a kidney improving function and application thereof, and belongs to the technical field of biological medicines.The xanthine oxidase inhibitory peptide is screened out by conducting enzymolysis, separation and purification on litopenaeus vannamei processing by-products and utilizing a molecular docking technology, the amino acid sequence of the xanthine oxidase inhibitory peptide is Pro-Leu-Gly-Pro-Pro-Pro, and the amino acid sequence of the xanthine oxidase inhibitory peptide is Pro-Leu-Gly-Pro-Pro-Pro. And the half inhibition concentration of the polypeptide is 2.356 + / -0.2448 mM. The xanthine oxidase inhibitory peptide is proved to have an improvement effect on hyperuricemia mice, the improvement effect is mainly characterized by reducing the content of serum uric acid, creatinine and urea nitrogen of the hyperuricemia mice, inhibiting the activity of xanthine oxidase (XOD) in serum and livers of the mice, inhibiting synthesis of uric acid and improving kidney injury of the mice, and Toxinpred prediction shows that the xanthine oxidase inhibitory peptide has the effect of inhibiting the activity of xanthine oxidase (XOD) in the serum and livers of the mice. The xanthine oxidase inhibitory peptide is free of toxic and side effects, so that the xanthine oxidase inhibitory peptide has a wide application prospect in preparation of food or drugs for improving renal functions.

Compositions and methods for administering ketone bodies to a subject include beta-hydroxybutyrate complexed with or coupled to at least one amino acid. The compositions and methods cause one or more of: weight loss, weight maintenance, reduced blood glucose level, maintenance of blood glucose level, increased muscle and physical performance, enhanced metabolic and cellular repair, improved detoxification and gut health, targeted bioavailability, sustained release and controlled absorption, increased metabolic efficiency, enhanced cellular uptake, minimized side effects, multifunctional therapeutics, improved focus, improved energy, improved cognitive function, improved mental acuity, treatment of traumatic brain injury, treatment of diabetes, treatment of neurological disorder, treatment of cancer, treatment of inflammatory condition, appetite suppression, anti-aging effects, anti-glycation effects, treatment of epilepsy, treatment of depression, improved performance, improved muscle mass, improved motor function, increased strength, increased metabolism, increased fat loss, increased fat oxidation, improved body composition, and improved mood.

The invention provides a virulent bacteriophage and application thereof, the virulent bacteriophage is named as vBVpaPChan1 and has been preserved in China Center for Type Culture Collection on December 10, 2024, the preservation address is Wuhan University, Wuhan, Hubei, China, and the preservation number is CCTCC M 20242772. The bacteriophage is safe, environmentally friendly and free of toxic and side effects, and compared with known bacteriophages, the bacteriophage is short in incubation period, large in outbreak amount and capable of effectively killing diseases caused by vibrio parahaemolyticus chan02.

The invention discloses a tumor disease assessment method based on big data, and particularly relates to the technical field of tumor disease assessment. Medical data and living habit data of a patient are collected through multiple data interfaces, integration is carried out through preprocessing and a multi-modal data fusion technology, tumor microenvironment features and drug metabolism features are extracted, a comprehensive feature vector is generated, the effectiveness of a chemotherapy regimen is predicted by using a machine learning model, and when the effectiveness of the chemotherapy regimen is low, the chemotherapy regimen is identified. Newest clinical tests and drug data are introduced regularly, model parameters are dynamically optimized in combination with the chemotherapy regimen improvement effect, it is ensured that the model reflects the newest clinical progress in real time, the problems of model updating lag and drug innovation mismatching are effectively solved, the accuracy and effectiveness of a treatment regimen are improved, and the treatment cost is reduced. And meanwhile, side effects caused by blind attempts are reduced, and powerful support is provided for personalized precise medical treatment.

An objective of the present disclosure is to provide anti-CD137 antigen-binding molecules which have immunocyte-activating effect, cytotoxic activity, or anti-tumor activity, and meanwhile have reduced effect on non-tumor tissues such as normal tissues and produce less side effects, and methods of using the same.Anti-CD137 antigen-binding molecules which have immunocyte-activating effect, cytotoxic activity, or anti-tumor activity, and meanwhile have reduced effect on non-tumor tissues such as normal tissues and produce less side effects, are provided by discovering and producing CD137 antigen-binding molecules whose binding activity to CD137 depends on various substances (for example, small molecule compounds) in target tissues. Methods of using the same, pharmaceutical formulations, and such are also provided.The present disclosure also provides an antigen-binding molecule whose binding activity to an antigen varies depending on a small molecule compound, a preparation method thereof, and uses thereof.

Systems and methods for providing recommended doses and instructions for pharmaceutical treatments, and more particularly systems and methods for measuring physiological and / or electrophysiological signals from a subject and providing recommended doses and instructions of pharmaceuticals based at least in part on the measured signals are described. Further, the recommended doses and instructions are based at least in part on a subject's disease(s), disorder(s), or injuries and / or symptom(s) of such, and / or side effects of medications or treatments the subject is receiving. The recommended doses and instructions are personally tailored to the subject to precisely and personally address the subject's needs, and may be based in part on correlation with database(s) comprising historical data of the subject and / or other subjects to treat the subject's movement disorders, injuries to the body or brain, cognitive diseases and disorders, sleep diseases and disorders, chronic pain, or other conditions.

The invention discloses application of lactobacillus rhamnosus HPT112 in preparation of a medicine for preventing and / or treating hyperuricemia, and belongs to the field of microorganisms, the lactobacillus rhamnosus HPT112 is preserved in the China Center for Type Culture Collection on November 20, 2023, and the preservation number is CCTCC NO: M20232273. Tests prove that the lactobacillus rhamnosus HPT112 has the function of regulating bile acid metabolism, so that the uric acid reducing effect is achieved, and the uric acid reducing effect equivalent to or even better than that of an existing hyperuricemia medicine can be achieved. Compared with existing hyperuricemia drugs, the lactobacillus rhamnosus HPT112 has the advantages that toxic and side effects are low, safety is high, a brand-new drug for preventing and / or treating hyperuricemia can be developed by the aid of the lactobacillus rhamnosus HPT112, and accordingly inflammatory reaction caused by hyperuricemia can be prevented and / or treated.

The invention relates to the technical field of intelligent follow-up visit, in particular to an intelligent follow-up visit system and method for daytime tumor patients, a medium and equipment, and the system comprises a physiological monitoring module, a drug interaction analysis module, a side effect mapping module, a health risk early warning module and an intelligent inquiry optimization module. According to the method, through continuous monitoring and real-time comparison of the physiological data of the patient and effective archiving of data fluctuation in a key period, instant and accurate reference is provided for clinical decision making, deep drug interaction analysis enables drug adjustment to be more targeted, unsuitable drug combinations are reduced, and therefore potential health risks of the patient are relieved; through side effect mapping, the system can predict and prevent potential side effects, the treatment safety is guaranteed, the risk early warning module enables the system to identify major health risks in the first time, the response speed of emergency medical events is improved, and the system can be used for improving the treatment efficiency by analyzing the interaction history of patients and optimizing the inquiry process. And the medical experience of the patient is more targeted and practical.

The invention discloses an application of betulinic acid 28-O-beta-D-glucoside (BA-6 for short) in preparation of a medicine for preventing and treating skin inflammation. The problems that an existing medicine for treating dermatitis is limited in curative effect, slow in effect taking, multiple in side effect, high in long-term use risk, large in individual difference, high in treatment cost, likely to cause immunoreaction and the like are solved. The invention discloses application of BA-6 in prevention and treatment of atopic dermatitis, contact dermatitis, eczema, rash, psoriasis, lupus erythematosus, papule squamous skin disease, pityriasis rosea, seborrheic dermatitis, pemphigus, celestial abscess, acne, tinea corporis, impetigo, SAPHO syndrome, hidradenitis suppurativa, dermatitis caused by drugs, lichen planus, pityriasis rubra pilaris, vitiligo, prurigo nodularis, dermatitis caused by drugs, and the like for the first time. The traditional Chinese medicine composition can be used for treating skin diseases, systemic sclerosis, hidradenitis suppurativa, granulomatous skin diseases, vitiligo, dermatomyositis, chronic skin itch and alopecia areata, and has the technical progress of obviously improving skin erythema, papule, edema, scale, moss and ulceration symptoms.

The invention discloses a drug full life cycle risk monitoring and early warning method based on multi-source data fusion, and relates to the technical field of data analysis, and the method comprises the steps: constructing a time sequence heterogeneous graph, calculating the similarity between drugs and side effect pairs in the time sequence heterogeneous graph through a comparative learning algorithm, and generating a candidate signal list; constructing a data set, and identifying hybrid factors associated with drug selection and side effect risks in the data set by using a separation characterization learning algorithm to obtain an average causal effect value; a space-time risk thermodynamic diagram is drawn, risks in the whole life cycle of the medicine are graded based on risk distribution characteristics in the space-time risk thermodynamic diagram, and a corresponding early warning strategy is triggered; and converting the early warning strategy into a risk assessment report in a standard format by using a preset report template. By accurately calculating the individual and average causal effect value, the causal relationship between the drug and the side effect of the drug is quantified, and a solid foundation is laid for deep evaluation of drug safety.

A bioenergy generator to increase the life force of a biological system is provided. The bioenergy generator includes fine pieces of natural stone, fine pieces of natural sand, fine pieces of metal, water and a supporting material operable to hold the natural sand, the natural stone, the metal, and the water together. Uses of the bioenergy generator are also provided, in particular, to enhance natural healing ability of a biological body and to treat a disease in a mammal, and to mitigate side effects of cancer treatments.

The invention discloses a wheat peptide with a hypoglycemic effect as well as a preparation method and application thereof, and belongs to the technical field of biological medicines. The invention provides a bioactive peptide LPQ or LPQF with a hypoglycemic effect, and animal model experiments prove that the bioactive peptide can effectively reduce the blood sugar level and improve related metabolic indexes, and has no obvious side effects. The invention also provides a wheat peptide rich in oligopeptide containing the peptide fragment LPQ, and animal model experiments prove that the wheat peptide has a remarkable effect in the aspect of reducing blood sugar. The invention provides a safe and effective alternative scheme for development of diabetes treatment drugs, and has good market prospects and application potential.

The invention provides an application of Ly93 in preparation of an anti-epileptic seizure drug, and provides a new thought for an epileptic seizure treatment drug. Research results show that the Ly93 can significantly reduce the grade of epileptic seizure in a KA-induced mouse epileptic seizure model, can significantly reduce the duration of PTZ-induced epileptic seizure, can significantly inhibit neuroinflammation in epileptic seizure, and does not affect the weight of a mouse. Therefore, the Ly93 serving as the epileptic seizure treatment medicine is remarkable in effect, relatively good in safety and relatively small in toxic and side effects.

The invention relates to an application of Danjie emodin in preparation of drugs for preventing or treating drug-induced liver injury. The liver injury is drug-induced liver injury induced by acetaminophen. According to the invention, the effective component Danleaf emodin in the traditional Chinese medicine rhubarb is used for preventing and treating drug-induced liver injury induced by acetamido, and the traditional Chinese medicine composition has the characteristics of safety, reliability and small toxic and side effects. Starting from the whole, multi-target intervention is performed on drug-induced liver injury induced by acetaminophen, the levels of glutamic-pyruvic transaminase, glutamic oxalacetic transaminase and malondialdehyde in plasma are remarkably reduced, the obvious anti-inflammatory and liver cell apoptosis inhibiting effects are achieved, the good clinical application prospect is achieved, and a new way is provided for prevention and treatment of liver injury.

The invention provides a dynamic medication dosage optimization method fused with reinforcement learning. The method comprises the following steps: acquiring a first physiological index parameter of a target patient; obtaining a first diagnosis report of the target patient, wherein the first diagnosis report comprises basic information of the target patient and first disease information of the target patient; the first disease information comprises a first disease type and first disease description information; determining a first reinforcement learning algorithm corresponding to the first disease type; determining a first control parameter of the first reinforcement learning algorithm according to the first physiological index parameter and the basic information; and performing operation on the first disease description information through the first reinforcement learning algorithm and the first control parameter to obtain a first medication dosage parameter. Based on the application, the drug effect can be consistent with the physical condition of a patient, and poor drug effect and excessive side effects caused by too strong drug effect are avoided.

The invention relates to an amido-substituted aromatic heterocycle inhibitor as well as a preparation method and application thereof. Specifically, the compound disclosed by the invention has a structure as shown in a formula (I), and each group is defined in the specification. The invention further discloses a preparation method of the compound and application of the compound as a KRAS mutation inhibitor. The compound has a very good inhibition effect on KRAS mutation and has better pharmacodynamic and pharmacokinetic performance and lower toxic and side effects. # imgabs0 #

The invention provides an inhalable tanshinone IIA lipid nanocrystal as well as a preparation method and application thereof, and the inhalable tanshinone IIA lipid nanocrystal is mainly formed by entrapping tanshinone IIA by using dipalmitoyl phosphatidylcholine DPPC and dipalmitoyl phosphatidyl ethanolamine DPPE as mixed phospholipids in the presence of a stabilizer. Compared with the prior art, the inhalable tanshinone IIA lipid nanocrystal disclosed by the invention has the advantages that by improving the physicochemical property and drug release behavior of TA, the lung retention volume of TA after aerosol inhalation is obviously increased, the retention time of TA in the lung is prolonged, and the risk of toxic and side effects caused by whole-body escape of drugs is reduced; the treatment effect on idiopathic pulmonary fibrosis is improved, and the compliance of a patient is improved.

The invention discloses a pharmaceutical composition for preventing and / or treating pain and application thereof.The pharmaceutical composition contains a Sigma-1 receptor antagonist and a histamine H3 receptor antagonist / inverse agonist and has a synergistic analgesic effect on various pains, the curative effect of the pharmaceutical composition is remarkably superior to that of a single drug, the use dosage of the single drug can be reduced, and therefore the side effect of single drug dosage dependence is reduced; good application prospects are realized.

The invention relates to application of 12-ketolithocholic acid in preparation of a medicine for preventing or treating acute ischemic intestinal injury. According to the application, 12-ketolithocholic acid (12-KLCA) is used for preventing or treating acute ischemic intestinal injury and is verified on a constructed classical intestinal ischemia reperfusion model, and a verification result shows that the 12-KLCA obviously improves intestinal histopathologic injury induced by intestinal ischemia reperfusion of a mouse, improves the survival rate of the mouse, and has a good application prospect in prevention or treatment of acute ischemic intestinal injury. The protein expression level of the apoptosis factor activated caspase-3 is reduced, the effect is obvious, safety and non-toxicity are achieved, and the side effect is small.

The invention relates to an antidepressant pharmaceutical composition and application thereof, and particularly discloses a pharmaceutical composition for treating depression as well as a preparation method and application thereof. The active pharmaceutical ingredients of the pharmaceutical composition are prepared from the following traditional Chinese medicines in parts by weight: 500 to 600 parts of radix bupleuri, 500 to 600 parts of fructus aurantii immaturus, 500 to 600 parts of radix aucklandiae, 500 to 600 parts of pericarpium citri reticulatae, 500 to 600 parts of rhizoma pinelliae preparata, 750 to 900 parts of herba taraxaci, 500 to 600 parts of scorched fructus crataegi, 300 to 360 parts of scorched semen arecae, 500 to 600 parts of paederia scandens, 300 to 400 parts of radix codonopsis, 300 to 400 parts of rhizoma corydalis and 500 to 600 parts of fried medicated leaven. The pharmaceutical composition has a remarkable curative effect on depression, animal experiments show that the pharmaceutical composition can remarkably enhance the social coefficient (showing that the pharmaceutical composition can improve social fear of depression patients) and improve sweet water preference (showing that the pharmaceutical composition is beneficial to transformation of negative emotions such as interest deficiency of the depression patients), and the pharmaceutical composition is safe to take, free of adverse reaction and toxic and side effects and free of toxic and side effects. And the composition can take effect quickly, and can take effect generally within 1-2 weeks after medication.

The invention discloses a preparation method of artemisia apiacea extracellular vesicles, which comprises the following steps: step 1, pre-treating artemisia apiacea, carrying out primary centrifugal treatment, removing large plant tissues and cell debris, carrying out secondary centrifugal treatment, filtering by a needle filter, and collecting; step 2, transferring the filtered suspension to a sucrose density gradient solution, then carrying out third centrifugal treatment, collecting the solution with the concentration of 30% in the layer, and carrying out fourth centrifugal treatment to obtain artemisia apiacea extracellular vesicles; the invention further discloses an artemisia apiacea extracellular vesicle, a pharmaceutical composition for treating cerebral apoplexy, a medicine and application of the artemisia apiacea extracellular vesicle in preparation of the medicine for treating cerebral apoplexy. The naturally-sourced vesicle delivery system provided by the invention is expected to have higher safety and lower toxic and side effects, and the enrichment concentration of the therapeutic component at the focus part of cerebral apoplexy is improved, so that the bioavailability and the treatment efficiency of the medicine are remarkably improved.

The invention relates to application of 1, 2, 3, 4, 6-O-pentagalloylglucose in preparation of a medicine for resisting cholestatic liver diseases, and belongs to the technical field of medicinal chemistry. The 1, 2, 3, 4, 6-O-pentagalloylglucose provided by the invention can be used for promoting bile acid excretion by reducing WDR6 protein expression. In-vivo and in-vitro experiments prove that the 1, 2, 3, 4, 6-O-pentagalloylglucose can be used for remarkably relieving the symptom of the cholestatic liver disease. In addition, the 1, 2, 3, 4, 6-O-pentagalloylglucose has no obvious toxic or side effect, and has no obvious influence on the liver function and the kidney function. The 1, 2, 3, 4, 6-O-pentagalloylglucose has a wide anti-cholestatic liver disease spectrum, and is suitable for various cholestatic liver diseases, such as primary biliary cholangitis (PBC), primary sclerosing cholangitis (PSC) and the like.

A drug combination of purinostat mesylate and an analog thereof for preventing and treating multiple myeloma, and the use thereof. Specifically, provided is a three-drug or four-drug combination of purinostat mesylate and an analog thereof, dexamethasone and other drug, which drug combination has significantly enhanced synergistic anti-tumor activity in vitro and in vivo, synergistically inhibits the expression of the key survival protein in multiple myeloma, is superior to existing clinical combination regimens, and has no significant toxic side effects. In addition, the drug combination significantly down-regulates the expression of CDK6, and overcomes the drug resistance to an immunomodulator. In particular, the three-drug combination of puisostat mesylate, a glucocorticoid and an immunomodulator has an excellent prevention and treatment effect on multiple myeloma, especially relapsed / refractory multiple myeloma.

The invention relates to colchicine transdermal delivery gel and a preparation method thereof. The colchicine transdermal delivery gel is prepared from the following components in percentage by weight: 0.3 percent to 0.7 percent of colchicine, 70.0 percent to 60.0 percent of a gel matrix, 29.5 percent to 39.5 percent of a dissolution promoter and 0 percent to 10 percent of a penetration enhancer. Wherein the gel matrix is prepared by dissolving a thickening agent in a mixed solvent of water and ethanol, the volume ratio of the water is 70%-10%, and the volume ratio of the ethanol is 30%-90%. According to the colchicine transdermal drug delivery gel provided by the invention, the colchicine transdermal drug delivery gel which is simple in formula and convenient to prepare is provided, and non-toxic and non-irritant materials are used, so that the irritation of colchicine oral preparations and injections is avoided, the toxic and side effects can be reduced, and relatively high drug delivery efficiency can be achieved.

The invention discloses an application of core proteoglycan or a coding gene thereof as a target spot in preparation of psoriasis treatment drugs, and a series of experiments prove that DCN can effectively protect mouse psoriasis-like dermatitis induced by imiquimod, improve skin scale, erythema, thickening and epidermal abnormal differentiation, enhance the barrier function of skin, improve the curative effect of psoriasis, and improve the curative effect of psoriasis. A large amount of infiltration of inflammatory cells is reduced, and a certain anti-inflammatory effect is achieved. Experimental research shows that the DCN has an obvious drug effect on a psoriasis model, is safe and efficient, has no side effect, is simple in production process and has the potential of realizing medical transformation. And the potential application value of the DCN on other various skin inflammatory diseases can be expanded.

Novel, inexpensive, and highly effective methods and devices for convenient and effective wound irrigation are described herein. Methods and devices disclosed herein utilize a synergistic combination of two or more antiseptic agents to reduce contact time, enhance antimicrobial effects, and reduce the likelihood of allergy and other side effects from the antiseptic agents in subjects. In one embodiment, devices include a discharge means for a reservoir housing containing irrigation solution wherein the discharge means has one or more specifically designed nozzles through which a sufficient volume of the irrigation solution can pass at an appropriate pressure.

The invention discloses radix ophiopogonis powder for relieving anxiety and improving sleep. The radix ophiopogonis powder is prepared by carrying out fermentation on radix ophiopogonis through plant lactobacillus GDMCC No. 64374 and carrying out enzymolysis treatment through pullulanase. The invention further discloses a preparation method and application of the radix ophiopogonis powder. The saponin content of the radix ophiopogonis powder is obviously increased. The radix ophiopogonis powder can be prepared into products in various forms, has the effects of relieving anxiety mood and improving sleep, is high in bioavailability and free of toxic and side effects, and can be eaten for a long time. Compared with the traditional radix ophiopogonis powder, the radix ophiopogonis powder disclosed by the invention is relatively low in safety risk and more obvious in effects of relieving anxiety mood and improving sleep.

The invention provides therapeutic methods, pharmaceutical compositions, and unit dose formulations for treating movement disorders, such as using a muscarinic acetylcholine receptor inhibitor in combination with a muscarinic acetylcholine receptor activator to treat dystonia. In some aspects, the invention provides a method of treating a movement disorder in a patient, where the method comprises administering to a patient in need thereof (i) a muscarinic acetylcholine receptor inhibitor in an amount effective to treat the movement disorder and (ii) a muscarinic acetylcholine receptor activator in an amount effective to reduce the frequency and / or magnitude of at least one side effect of the muscarinic acetylcholine receptor inhibitor, to thereby treat the movement disorder.

The invention discloses poplar and phellinus igniarius polysaccharide SVP-1 as well as a preparation method and application thereof, and belongs to the field of biological medicines. The poplar phellinus igniarius polysaccharide SVP-1 provided by the invention has remarkable anti-tumor activity, and can effectively inhibit proliferation, invasion and migration of tumor cells so as to block malignant progression of tumors. The structure is clear, the preparation method is controllable, the stability and biological activity of polysaccharide components are ensured, and a reliable basis is provided for development of antitumor drugs. When the traditional Chinese medicine composition is used together with radiotherapy and chemotherapy medicines, a synergistic effect can be achieved, the sensitivity of tumors to treatment can be improved, the toxic and side effects of radiotherapy and chemotherapy can be relieved, and the effects of reducing toxicity and increasing efficiency are achieved. According to the combined treatment strategy, the curative effect of the existing tumor therapy can be remarkably improved, meanwhile, adverse reactions are reduced, and a new optimization scheme is provided for clinical tumor treatment.